Clinical trial
NGR015: Randomized double-blind phase III study of NGR-hTNF plus best investigator�s choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM)
To compare overall survival (OS) in patients randomized to NGR-hTNF plus BIC (Best Investigator Choice) versus patients randomized to placebo plus BIC
| Category | Value |
|---|---|
| Study start date | 2010-10-26 |